EOC Pharma, a Shanghai oncology company, announced approval to start a China Phase II trial of a novel immunotherapy for patients with metastatic breast cancer. EOC in-licensed China rights to EOC202 (eftilagimod alpha) from Immutep of Australia . Efti, a soluble LAG-3 fusion protein (LAG-3Ig), is a novel antigen presenting cell (APC) activator being tested in cancer and infectious disease. It will be administered in combination with paclitaxel. EOC was spun out of China in-licensing company Eddingpharm in 2015. More details.... Stock Symbols: (ASX: IMM; NSDQ: IMMP) Share this with colleagues: // //